Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
CEO Faraz Ali is scheduled to present on Thursday, June 4, 2026, at 3:10 p.m. ET, with live and archived webcasts available via Tenaya’s investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TNYA
On May 29, the day this news came out, TNYA closed 8.77% above the previous close.
Data tracked by StockTitan Argus for the May 29 session.
Key Figures
- Net loss
- $19.3 million
- Q1 2026 net loss from 10-Q/8-K
- Cash & equivalents
- $80.9 million
- Cash as of March 31, 2026 (10-Q/8-K)
- Collaboration revenue
- $0.2 million
- Collaboration revenue in Q1 2026 (10-Q)
- Alnylam upfront fee
- $10.0 million
- Fixed upfront platform access fee in Alnylam collaboration
- Potential milestones
- $1.1 billion
- Potential milestones from Alnylam collaboration (10-Q)
- 2025 net loss
- $90.6 million
- Full-year 2025 net loss from 8-K
- Year-end cash
- $100.5 million
- Cash and marketable securities at Dec 31, 2025 (8-K)
- Offering proceeds
- $55.8 million
- Net proceeds from December 2025 underwritten offering (8-K)
Historical Context
-
Positive interim RIDGE-1 TN-401 data with EMA PRIME designation for PKP2 ARVC.
-
Q1 2026 results with $80.9M cash, Alnylam deal, and 2026 clinical readout plans.
-
Announcement of late-breaking RIDGE-1 TN-401 oral presentation and ASGCT abstracts.
-
Q4/FY 2025 results with $100.5M cash and December offering bolstering balance sheet.
-
Preclinical TN-301 DMD data and Phase 1 safety supporting plans for Phase 2 development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya’s Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET.
The live webcast of the presentation may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.